Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”), today announced that the record date for the spin-off and distribution of shares of common stock, par value $0.0001 per share, ...

Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the digital wellness technology company, announces that it anticipates a delay in the filing of the ...

Court-Approved Bidding Procedures 23andMe is requiring all bidders in the court-supervised marketing process to guaranty that they will comply with the Company’s privacy policies and applicable law.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Louvain-la-Neuve, Belgium, April 18th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA ...

Louvain-la-Neuve, Belgique, 18 avril 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Prime Biome is generating buzz as a potential “gut-skin miracle” for those seeking clearer skin and better digestion.

Through the promotion of skin health from the inside out, Prime Biome is designed to provide a risk-free and natural approach ...

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- The CrazyBulk line of products are designed as a legal and safer alternative to ...

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) Approval based on Phase 3 trials demonstrating Dupixent ...